Randomized phase II trial of the prophylactic use of celecoxib for the prevention of oxaliplatin-related peripheral vascular pain in Capeox (YCOG1205)
- 104 Downloads
Capeox is widely used as an adjuvant chemotherapy regimen of colorectal cancer that does not require central vein catheter insertion. However, oxaliplatin-related vascular pain with peripheral administration is a major adverse event. We assessed the preventive effect of Celecoxib on oxaliplatin-related vascular pain.
A multicenter study of the Yokohama Clinical Oncology Group (YCOG) in Japan. This study was an open label, randomized non-comparative phase II study between Capeox without Celecoxib (C+ Group) and with it (C− group). The primary endpoint was the appearance frequency of grade ≥ 2 vascular pain according to the Verbal Rating Scale (VRS).
Between October 2012 and February 2014, 81 patients were recruited to this study and randomly divided into 2 groups: 38 patients in the C− group and 39 patients in the C+ group. Four cases were excluded at the analysis stage because they had not received the allocated intervention. The rate of grade ≥ 2 vascular pain was 55.3% in the C− group and 53.8% in the C+ group (p = 1.000).
Celecoxib was unable to prevent oxaliplatin-related vascular pain in this study. However, it may be able to decrease the vascular pain that patients already have.
KeywordsOxaliplatin Vascular pain Celecoxib Colon cancer Capeox
I wish to thank all of the doctors, pharmacists, and nurses concerned with this trial.
Compliance with ethical standards
Conflict of interest
The authors declare that they have no competing interests.
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
Informed consent was obtained from all individual participants included in the study.
- 2.Kuebler JP, Wieand HS, O’Connell MJ, Smith RE, Colangelo LH, Yothers G, Petrelli NJ, Findlay MP, Seay TE, Atkins JN (2007) Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07. J Clin Oncol 25(16):2198–2204CrossRefPubMedGoogle Scholar
- 3.André T, Boni C, Navarro M, Tabernero J, Hickish T, Topham C, Bonetti A, Clingan P, Bridgewater J, Rivera F (2009) Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol 27(19):3109–3116CrossRefPubMedGoogle Scholar
- 6.Yoshida Y, Hoshino S, Aisu N, Naito M, Tanimura S, Mogi A, Tanaka T, Hirata K, Tamura K, Yamashita Y (2015) Administration of chemotherapy via the median cubital vein without implantable central venous access ports: port-free chemotherapy for metastatic colorectal cancer patients. Int J Clin Oncol 20(2):332–337. https://doi.org/10.1007/s10147-014-0703-5 CrossRefPubMedGoogle Scholar
- 7.Sakamoto C, Kawai T, Nakamura S, Sugioka T, Tabira J (2013) Comparison of gastroduodenal ulcer incidence in healthy Japanese subjects taking celecoxib or loxoprofen evaluated by endoscopy: a placebo-controlled, double-blind 2-week study. Aliment Pharmacol Ther 37(3):346–354. https://doi.org/10.1111/apt.12174 CrossRefPubMedGoogle Scholar
- 8.Bertagnolli MM, Eagle CJ, Zauber AG, Redston M, Solomon SD, Kim K, Tang J, Rosenstein RB, Wittes J, Corle D, Hess TM, Woloj GM, Boisserie F, Anderson WF, Viner JL, Bagheri D, Burn J, Chung DC, Dewar T, Foley TR, Hoffman N, Macrae F, Pruitt RE, Saltzman JR, Salzberg B, Sylwestrowicz T, Gordon GB, Hawk ET (2006) Celecoxib for the prevention of sporadic colorectal adenomas. N Engl J Med 355(9):873–884. https://doi.org/10.1056/NEJMoa061355 CrossRefPubMedGoogle Scholar
- 9.Bertagnolli MM, Eagle CJ, Zauber AG, Redston M, Breazna A, Kim K, Tang J, Rosenstein RB, Umar A, Bagheri D, Collins NT, Burn J, Chung DC, Dewar T, Foley TR, Hoffman N, Macrae F, Pruitt RE, Saltzman JR, Salzberg B, Sylwestrowicz T, Hawk ET (2009) Five-year efficacy and safety analysis of the adenoma prevention with celecoxib trial. Cancer Prev Res (Phila) 2(4):310–321. https://doi.org/10.1158/1940-6207.capr-08-0206 CrossRefGoogle Scholar
- 10.Arber N, Eagle CJ, Spicak J, Racz I, Dite P, Hajer J, Zavoral M, Lechuga MJ, Gerletti P, Tang J, Rosenstein RB, Macdonald K, Bhadra P, Fowler R, Wittes J, Zauber AG, Solomon SD, Levin B (2006) Celecoxib for the prevention of colorectal adenomatous polyps. N Engl J Med 355(9):885–895. https://doi.org/10.1056/NEJMoa061652 CrossRefPubMedGoogle Scholar
- 12.Atari-Hajipirloo S, Nikanfar S, Heydari A, Noori F, Kheradmand F (2016) The effect of celecoxib and its combination with imatinib on human HT-29 colorectal cancer cells: Involvement of COX-2, Caspase-3, VEGF and NF-kappaB genes expression. Cell Mol Biol (Noisy-le-grand) 62(2):68–74Google Scholar
- 13.Sakoguchi-Okada N, Takahashi-Yanaga F, Fukada K, Shiraishi F, Taba Y, Miwa Y, Morimoto S, Iida M, Sasaguri T (2007) Celecoxib inhibits the expression of survivin via the suppression of promoter activity in human colon cancer cells. Biochem Pharmacol 73(9):1318–1329. https://doi.org/10.1016/j.bcp.2006.12.033 CrossRefPubMedGoogle Scholar
- 14.Egashira I, Takahashi-Yanaga F, Nishida R, Arioka M, Igawa K, Tomooka K, Nakatsu Y, Tsuzuki T, Nakabeppu Y, Kitazono T, Sasaguri T (2017) Celecoxib and 2,5-dimethylcelecoxib inhibit intestinal cancer growth by suppressing the Wnt/beta-catenin signaling pathway. Cancer Sci 108(1):108–115. https://doi.org/10.1111/cas.13106 CrossRefPubMedGoogle Scholar
- 18.Matsuyama K, Mishima H, Ueno H, Kajihara K, Morioka A, Morimoto S, Yamauchi K, Honda Y, Komori K, Tsujinaka T (2011) Etiology and management of venous pain during intravenous administration of oxaliplatin. Jpn J Cancer Chemother 38(3):411–414Google Scholar
- 19.Cathomas R, Koberle D, Ruhstaller T, Mayer G, Rass A, Mey U, von Moos R (2010) Heated (37 degrees C) oxaliplatin infusion in combination with capecitabine for metastatic colorectal carcinoma: can it reduce neuropathy? Support Care Cancer 18(10):1263–1270. https://doi.org/10.1007/s00520-009-0740-1 CrossRefPubMedGoogle Scholar
- 22.Yoshida Y, Hoshino S, Aisu N, Shiwaku H, Beppu R, Tanimura S, Yamashita Y (2012) Dexamethasone as a means not only for controlling vascular pain caused by the administration of oxaliplatin via the peripheral vein but also for controlling oxaliplatin-induced hypersensitivity reactions. Br J Med Med Res 2(2):132–141CrossRefGoogle Scholar
- 23.Shiotsuka Y, Uebuchi M, Hamada S, Morita N, Moriyama A, Yamashita M, Ichikawa Y, Fujii H, Matsuo A, Kuhara H, Ikuta Y, Ikeshima S, Kuramoto M, Fujii K, Shimada S (2012) Reduction of angialgia during peripheral administration of oxaliplatin mixed with dexamethasone. Gan To Kagaku Ryoho 39(10):1583–1586PubMedGoogle Scholar
- 26.Nagao S, Furihata M, Fukagawa K, Furihata T, Matsuhashi Y, Wada T (2017) Premedication with fast-acting oxycodone hydrochloride hydrate effectively reduced oxaliplatin-induced severe vascular pain. J Infect Chemother 23(7):493–497. https://doi.org/10.1016/j.jiac.2017.02.006 CrossRefPubMedGoogle Scholar
- 27.Solomon SD, McMurray JJ, Pfeffer MA, Wittes J, Fowler R, Finn P, Anderson WF, Zauber A, Hawk E, Bertagnolli M (2005) Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 352(11):1071–1080. https://doi.org/10.1056/NEJMoa050405 CrossRefPubMedGoogle Scholar
- 28.Solomon SD, Wittes J, Finn PV, Fowler R, Viner J, Bertagnolli MM, Arber N, Levin B, Meinert CL, Martin B, Pater JL, Goss PE, Lance P, Obara S, Chew EY, Kim J, Arndt G, Hawk E (2008) Cardiovascular risk of celecoxib in 6 randomized placebo-controlled trials: the cross trial safety analysis. Circulation 117(16):2104–2113. https://doi.org/10.1161/circulationaha.108.764530 CrossRefPubMedPubMedCentralGoogle Scholar